Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis Inc (PSNL) drives innovation in genome-guided medicine through advanced sequencing solutions and cancer immunotherapy research. This news hub provides investors and researchers with essential updates on the company’s scientific advancements and strategic developments.
Access authoritative reporting on PSNL’s financial results, clinical trial milestones, and technology partnerships. Our curated collection includes press releases on pharmacogenomics breakthroughs, regulatory filings, and collaborative research initiatives shaping personalized medicine.
Key coverage areas include precision oncology developments, genomic data platform enhancements, and biopharma collaborations. Stay informed about innovations in neoantigen discovery and therapeutic vaccine development through verified primary sources.
Bookmark this page for real-time updates on Personalis’ contributions to next-generation diagnostics and therapeutic solutions. Monitor critical updates through our organized repository of corporate communications and third-party analysis.
Personalis (NASDAQ: PSNL) announced two significant agreements: a $50 million investment from Merck through private placement stock purchase at $3.56 per share, and a multi-year extension of its collaboration with Moderna. The investment will give Merck approximately 16.5% ownership stake in Personalis, representing about 14 million shares.
The extended collaboration involves Personalis' ImmunoID NeXT Platform® being used for V940/mRNA-4157, an investigational individualized neoantigen therapy being jointly developed by Merck and Moderna. Personalis has been providing its tumor-profiling platform to both companies since the beginning of the V940/mRNA-4157 clinical development program.
Personalis (Nasdaq: PSNL) and Tempus AI (Nasdaq: TEM) have expanded their commercial relationship to benefit the biopharma industry. Originally agreed upon in November 2023, the collaboration aims to bring ultra-sensitive MRD testing to market. The partnership was launched at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, with Tempus serving as the exclusive commercial diagnostic partner for Personalis' NeXT Personal® Dx. This product is designed for broad patient adoption in breast and lung cancers and immunotherapy monitoring across all solid tumors.
Following a positive market reaction, Tempus will now offer Personalis' NeXT Personal MRD product to pharmaceutical and biotech customers. These customers can bundle MRD testing with other Tempus offerings within a given study. Chris Hall, CEO of Personalis, believes that this expansion will accelerate market penetration and capitalize on new opportunities.
Personalis (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, has announced its participation in two upcoming investor conferences. The company will join the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, featuring a fireside chat at 12:30 PM ET at The Lotte New York Palace. Additionally, Personalis will participate in TD Cowen's Diagnosing Tomorrow: Tools & Technologies for the Next Decade conference on December 12, 2024, contributing to a panel discussion on 'MRD - The Future Tech Stack' at 1:30 PM ET at One Vanderbilt in New York.
Personalis (PSNL) reported strong Q3 2024 financial results with total revenue of $25.7 million, up 41% year-over-year. Biopharma revenue grew 96% to $15.7 million, while Enterprise revenue decreased 33% to $5.3 million. The company raised approximately $62.2 million through various financing activities, including transactions with Tempus AI and ATM program sales. Cash position stands at $143.7 million, extending runway into H1 2027. The company increased its full-year 2024 revenue guidance to $83-84 million, up from previous $79-81 million, despite reporting a net loss of $39.1 million for Q3.
Personalis, a leading company in advanced genomics for precision oncology, has announced its participation in the Stifel 2024 Healthcare Conference. The company's management team is scheduled to present on Tuesday, November 19, at 10:55 a.m. Eastern Time. The presentation will take place at the Lotte New York Palace Hotel in New York, NY.
Personalis (Nasdaq: PSNL) has scheduled its third quarter 2024 financial results announcement for Wednesday, November 6, 2024. The company will host a conference call and webcast at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on the same day to discuss the results and recent highlights. Investors can join via phone (877-451-6152 domestic, 201-389-0879 international) or through the company's website. A replay will be available and archived online after the call.
Personalis, Inc. (Nasdaq: PSNL) presented compelling data at ESMO 2024 for its NeXT Personal® MRD test. Two studies showcased the test's effectiveness in lung cancer monitoring and immunotherapy response assessment. The TRACERx study, analyzing over 400 NSCLC patients, demonstrated strong detection rates for residual lung cancer post-surgery, with 42% of detections in the ultrasensitive range. The test showed high sensitivity in detecting early-stage recurrence months ahead of imaging. Another study by VHIO, involving 200+ late-stage cancer patients on immunotherapy, revealed that significant ctDNA level decreases correlated with longer overall survival. These findings underscore the importance of ultrasensitive MRD testing in cancer management and therapy response monitoring.
Personalis, a leader in advanced genomics for precision oncology, has announced its participation in two upcoming investor conferences. The company's management team will be present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, where they will give a presentation at 4:50 pm Eastern Time at the Marriott Marquis in New York. Additionally, Personalis will attend the Lake Street 8th Annual Best Ideas Growth (BIG) Conference on September 12, 2024, at the Yale Club in New York.
These conferences provide Personalis with opportunities to showcase their advancements in genomics and precision oncology to potential investors and industry professionals. The company's participation in such events demonstrates its commitment to engaging with the investment community and sharing its vision for the future of personalized cancer care.
Personalis (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, has announced the granting of a non-qualified stock option to its new Executive Director of Market Access & Reimbursement. The Compensation Committee of the Board of Directors approved this grant on August 15, 2024, under the company's 2020 Inducement Plan.
The stock option allows for the purchase of 75,000 shares of Personalis' common stock at an exercise price of $5.07 per share, equal to the closing price on the grant date. The option vests over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years, subject to continued service.
Personalis (PSNL) and Tempus (TEM) have expanded their commercial collaboration, with Tempus investing $36 million in Personalis. This investment includes exercising warrants to purchase 9.2 million shares at an average price of $2.00 and buying an additional 3.5 million shares at $5.07 each. The expansion follows strong demand for their ultra-sensitive MRD testing in breast and lung cancers, as well as immunotherapy monitoring across solid tumors.
Key points of the expanded collaboration include:
- Tempus accelerating commercialization efforts over the first two years
- Personalis increasing the quantity of patient samples it will accept
- Tempus becoming the exclusive commercial partner for Personalis' MRD product
- Tempus owning approximately 19.3% of Personalis' outstanding common stock after the transaction
